Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ypsomed Holding AGXSWX:YPSN +2.04%91 EV-to-EBIT is 21.96 as of Jul. 28, 2026, which is 60% below its 10-year median of 55.24. GuruFocus rates XSWX:YPSN with a GF Score™ of 91/100 and a GF Value™ of CHF396.12 (Fairly Valued). The stock has 6 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Ypsomed Holding AG ranks worse than 60.3% on this metric.
The historical rank and industry rank for Ypsomed Holding AG's EV-to-EBIT or its related term are showing as below:
XSWX:YPSN'
s EV-to-EBIT Range Over the Past 10 Years
Min: 16.17 Med: 55.24 Max: 324.72
Current: 21.96
During the past 13 years, the highest EV-to-EBIT of Ypsomed Holding AG was 324.72. The lowest was 16.17. And the median was 55.24.
XSWX:YPSN's EV-to-EBIT is ranked worse than 60.3% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 18.67
vs XSWX:YPSN: 21.96
Ypsomed Holding AG (XSWX:YPSN) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ypsomed Holding AG's Enterprise Value for the quarter that ended in Mar. 2026 was CHF3,860.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ypsomed Holding AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was CHF244.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ypsomed Holding AG EV-to-EBIT Related Terms
Ypsomed Holding AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Ypsomed Holding AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:YPSN vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Ypsomed Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ypsomed Holding AG EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ypsomed Holding AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ypsomed Holding AG's EV-to-EBIT falls into.
Ypsomed Holding AG's current Enterprise Value is CHF5,362.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ypsomed Holding AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was CHF244.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ypsomed Holding AG (XSWX:YPSN) has a EV-to-EBIT of 21.96 as of Jul. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ypsomed Holding AG and its competitors. This is 60% below median its historical median of 55.24. Over the past decade, Ypsomed Holding AG's EV-to-EBIT has ranged from 16.17 to 324.72. According to the industry distribution chart, Ypsomed Holding AG ranks #281 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 60.3%.
Is Ypsomed Holding AG's EV-to-EBIT too high?
Ypsomed Holding AG's current EV-to-EBIT of 21.96 is 60% below median its 10-year median of 55.24. Over the past 10 years, this metric has ranged from a low of 16.17 to a high of 324.72. The Medical Devices & Instruments industry median EV-to-EBIT is 18.67. Ypsomed Holding AG's value of 21.96 is 17.6% above this industry median. Based on the distribution chart, Ypsomed Holding AG ranks #281 out of 466 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Ypsomed Holding AG has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ypsomed Holding AG ranks #281 out of 466 companies for EV-to-EBIT. This places Ypsomed Holding AG in the lower half of its industry. The industry median EV-to-EBIT is 18.67. Ypsomed Holding AG's value of 21.96 is 17.6% above this benchmark. Historically, Ypsomed Holding AG's own EV-to-EBIT has ranged from 16.17 to 324.72 over the past decade. While the company's 10-year median is 55.24 vs. the industry median of 18.67, Ypsomed Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.67, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ypsomed Holding AG's current EV-to-EBIT of 21.96 is 17.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ypsomed Holding AG and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ypsomed Holding AG's current EV-to-EBIT is 21.96, which is 60% below median its own 10-year median of 55.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (XSWX:YPSN) is currently considered Fairly Valued. The stock's GF Value™ is CHF396.12, compared to a current price of CHF390.20 — trading 1.5% below its estimated fair value. The current EV-to-EBIT is 21.96, which is 60% below median its 10-year median of 55.24 and 17.6% above the Medical Devices & Instruments industry median of 18.67. Ypsomed Holding AG's overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ypsomed Holding AG (XSWX:YPSN), the current EV-to-EBIT is 21.96 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ypsomed Holding AG (XSWX:YPSN) Overvalued in 2026?
Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued.
The current stock price of CHF390.20 is trading 1.5% below its estimated GF Value™ of CHF396.12.
GuruFocus considers Ypsomed Holding AG to be Fairly Valued.
Key valuation signals for XSWX:YPSN:
EV-to-EBIT: 21.96 (60% below median its 10-year median of 55.24)
GF Value™: CHF396.12 vs. price of CHF390.20 (1.5% below fair value)
Industry Position: 17.6% above the Medical Devices & Instruments median (#281 of 466)
No single metric tells the full story. See the XSWX:YPSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
91GF Score
Get the complete analysis for XSWX:YPSN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:YPSN has been successfully added to your 
